Abstract
The treatment of patients with metastatic testicular cancer is multimodal. Postchemotherapy retroperitoneal lymph node dissection is a technically demanding procedure that can benefit appropriately selected patients. In this article, we review postchemotherapy retroperitoneal lymph node dissection, including indications, technical updates, and the management and outcomes of patients who undergo surgery. Many aspects continue to evolve, and we review the evidence regarding current controversies in the field.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.